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Abstract
Background
Musculoskeletal symptoms in people living with HIV (PLWH) such as pain, joint stiffness,
and fatigue are commonly reported. Prevalence rates of up to 45%, 79% and 88% respec-
tively have been reported. However, very little is known about differences in prevalence and
impact of musculoskeletal symptoms on physical functioning and quality of life of PLWH on
effective combined antiretroviral treatment (cART) in high and low-resource settings.
Methods
A cross-sectional study of PLWH on effective cART enrolled from two large urban clinics in
the UK and Zambia was conducted in 2016. Eligible participants had no history of trauma to
the joints within 4 weeks of recruitment, or documented evidence of previous rheumatic dis-
ease. Current musculoskeletal symptoms, functional ability, and health-related quality of life
were evaluated using the health assessment (HAQ) and quality-of-life short form (SF-36)
self-reported questionnaires.
Results
214 patients were enrolled (108:UK and 106:Zambia). Participants from Zambia were youn-
ger (47 vs 44 years) and had significantly lower CD4 counts (640 vs 439 cells/mL p = 0.018)
compared to those from the UK, while the UK group had lived with HIV longer (11 vs 6
years; p<0.001) and reported more comorbidities than the Zambian group (66% vs 26%;
p<0.001). Musculoskeletal pain was common in both groups (UK:69% vs Zambia:61% p =
0.263) but no significant differences in physical functional capacity between the groups
were observed. However, the UK group had significantly worse quality of life measurements
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Conclusions
Musculoskeletal symptoms in PLWH from both the UK and Zambia were common. PLWH in
the UK reported worse quality of life measures associated with musculoskeletal symptoms
compared to those in Zambia, suggesting that factors such as mental health, patient expec-
tations and multimorbidity might play a role in determining well-being and quality of life of
PLWH with musculoskeletal symptoms.
Introduction
The introduction of combination antiretroviral treatment (cART) has meant that people living
with HIV (PLWH) in many parts of the world can now expect to experience a near-normal life
expectancy, providing a good CD4 cell count response and undetectable viral load are achieved
[1, 2]. However, due to the availability of cART the cohort of PLWH globally is ageing and
therefore the prevalence of age-associated co-morbidities such as cardiovascular disease,
chronic kidney disease, osteoporosis and non-AIDS malignancies are expected to increase [3].
Before cART musculoskeletal symptoms such as pain were a common symptom of end-
stage HIV, but there is growing evidence that musculoskeletal symptoms including arthralgia,
myalgia, and soft tissue rheumatism are common in PLWH on effective cART in the absence
of established rheumatological disease [4, 5]. Prevalence of musculoskeletal symptoms among
HIV-infected adults has been reported to be between 10% to 45% in both low and high
resource settings [4, 6–8]. Pain has been reported to be one of the most common physical
symptoms among PLWH, with reported prevalence ranging from 30% to 83% [6, 9]. Musculo-
skeletal symptoms among PLWH have both clinical and public health importance. Not only
are symptoms such as musculoskeletal pain associated with psychological distress, emotional
problems, poor quality of life and suicidal ideation [10, 11], but they are also known to impact
on activities of daily living [12] and are associated with higher rates of sick leave, loss of
employment and lower satisfaction with health care [13]. Among PLWH, pain is also associ-
ated with poorer adherence to cART [14] and missed clinic visits [15].
Whilst pain has been identified as a prevalent problem in PLWH, other musculoskeletal
symptoms have been largely neglected in clinical practice, and little research has been con-
ducted on this area either in low and high-income settings in the modern ART era among
individuals in whom HIV infection is largely controlled. With the aim to determine indepen-
dently the prevalence and impact of musculoskeletal symptoms in two countries which are cul-
turally and demographically different in terms of the HIV epidemic, we report the prevalence
and impact of these symptoms on quality of life and physical activity among a group of PLWH
in the United Kingdom and Zambia. We further compare both groups in an exploratory way
to determine first if there are differences and second the type of variables where those differ-
ences are found to inform any future studies and interventions.
Materials and methods
Study design and setting
A cross-sectional study of PLWH on effective cART enrolled from two large urban clinics in
the UK and Zambia was conducted. Participants from Zambia were recruited from a large
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clinic at the University Teaching Hospital (UTH) in Lusaka where HIV care is provided
according to the national guidelines [16]. Participants from the UK were recruited from a
clinic in Brighton. Several factors make Lusaka and Brighton ideal for conducting this
research. The UTH is the largest hospital in Zambia with a dedicated HIV department treating
many PLWH daily. Brighton has the largest HIV population outside of London, with a preva-
lence of 7.96/1000 of the general population aged 15–59 [17] and a single clinic where 90% of
the local diagnosed population attend for HIV care.
Assuming a 45% prevalence estimate of musculoskeletal symptoms, based on an average
prevalence calculated from previous research papers [4, 6–8], the total sample size of 105 par-
ticipants from each location is required with a desired precision of 8% and 90% confidence
level. This level of confidence and sample size was deemed sufficient for the scope of this
small-scale cross-sectional survey. Our study was not powered to determine a clinically impor-
tant difference in the prevalence of symptoms in the two countries.
Ethics approval was obtained from the Biomedical Research Ethics Committee of the Uni-
versity of Zambia, the Research and Ethics and Governance Committee in Wales and the UK
Health Research Authority (HRA); Reference: 16/WA/0285. Written informed consent was
obtained from all patients.
Participants and inclusion and exclusion criteria
Eligible participants were>18 years of age, with no documented prior history of rheumatolog-
ical disease. Participants with a known rheumatic comorbidity were thus excluded as the aim
off the survey is to assess the prevalence of rheumatic-type symptoms in PLWH not known to
have a rheumatic disease. Participants with a history of trauma to the joints within 4 weeks of
recruitment were excluded. ‘Four weeks’ no history of trauma to the joints was deemed suffi-
cient time for a possible trauma to the joints to have resolved and therefore would not attribute
to the reasoning behind a participant experiencing musculoskeletal symptoms.
Participants who consented to participate completed a series of paper-based self-reporting
questionnaires evaluating musculoskeletal symptoms, functional ability, and health-related
quality of life. A symptom was defined as a subjective loss of normal function or feeling which
was recognized by the person experiencing them. All questionnaires were translated into
Bemba and Nyanja (Zambia’s most common languages) and facilitated by a research assistant
fluent in both languages who was able to explain in detail how to complete the questionnaires
if needed (see S2, S3, S4, S6, S7, S8 and S9 Files for questionnaires used in Bemba, Nyanja and
English).
Outcome measures
Assessment of musculoskeletal symptoms. A questionnaire, previously validated
amongst PLWH for its usefulness in identifying the presence, type and frequency of musculo-
skeletal symptoms [18] was used to collect the data, containing questions on symptoms such as
muscle and joint pain, joint swelling, joint movement, and fatigue. Other symptoms involving
the skin, eyes, and mouth were also documented. Pain and fatigue were evaluated using a
10-point numeric visual analogue scale from 0 to 10 (0 = no symptoms, 10 = severe symptoms)
of how much pain or fatigue participants experienced S9 File [19, 20].
Assessment of physical functioning. Physical functioning was evaluated using the Stan-
ford Health Assessment Questionnaire (HAQ), an instrument originally developed for rheu-
matology to assess patient’s capacity to perform activities of daily living [21, 22] but has since
been validated and applied to PLWH across diverse disciplines and various cultures [23, 24].
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The HAQ queries the ability to perform 20 activities of daily living divided into 8 categories.
The ability to perform each activity has four possible responses (0 = no difficulty, 1 = some dif-
ficulty, 2 = much difficulty, to 3 = unable to do). The total HAQ score is calculated from the
mean of the scores for each category as previously reported [25].
To adapt the HAQ culturally, modifications of individual items are sometimes necessary.
These have proved equally as reliable and valid as their parent [26]. If there were any types of
items that needed adaptation an appropriate substitution in keeping with the original intent of
the item was made by the research assistant.
Assessment of quality of life. Health-related quality of life (QoL) was measured using the
quality of life short form (SF-36). The SF-36 is a generic measure of QoL that has been widely
validated and noted to be reliable for use across a range of healthcare professions, settings, and
patients including PLWH [27–31]. It measures QoL across eight emotional and physical
domains: physical functioning; role limitations due to physical health; role limitations due to
emotional problems; energy/fatigue; emotional well-being; social functioning; pain; general
health. In the SF-36 a score of 0 represents the worst possible QoL, and 100 indicates full QoL.
Variables. All information regarding the patient‘s sociodemographic characteristics such
as age and years since diagnosis (years), gender (female or male), education (primary, second-
ary, college, university) smoking habits (smoker or non-smoker), work status (employed or
unemployed), number of comorbidities (>2 or <2), on cART (yes or no) and type of cART
(protease inhibitor-based therapy, integrase-inhibitor based therapy, NNRTI-based therapy,
complex regimen >1 of the aforementioned) was collected using a specific form designed for
this research (see S1, S5 and S10 Files). Clinical test results including current CD4 count (cells/
mm3) and viral load (>40 copies/ml or <40 copies/ml defined as an undetectable viral load)
were recovered for each patient.
Any additional clinical and sociodemographic data was obtained from the medical notes.
Statistical analysis
Differences in baseline demographics, clinical and HIV parameters between the UK and the
Zambia cohorts were determined using Chi-square, Fisher’s exact test, t-test or Mann-Whit-
ney test depending on data–set size and type and normality of the data. Multiple linear regres-
sion models were used to predict three SF-36 domains (general health, vitality and mental
health). The other domains were not predicted due to heavily skewed data. The models used
demographic factors (age, gender, smoking status, presence of co-morbidities, work status and
CD4 count) and musculoskeletal symptoms (presence of reduced joint movement, presence of
morning joint or muscle stiffness, muscle pain severity and fatigue severity). Of note, the P-P
plots for the Zambia general health and mental health models suggest that the assumption of
normality for the residuals may have been violated. However, these are mild deviations and so
the results are likely still valid. Participants not on ART were excluded from the regression
analyses. All statistical analyses were performed using SPSS (IBM Version 24).
Results
Demographics and clinical characteristics
108 participants in the UK and 106 in Zambia were enrolled. Table 1 describes the demograph-
ics and clinical characteristics for both study groups. Participants from the UK were mainly
male, men that have sex with men, slightly older (mean age 47 vs 44 years old), had been living
with HIV for longer (11 vs 6 years), and were more likely to have more than 2 comorbidities
(66% vs 26%) compared to the Zambian participants. Zambian participants were mainly
female, heterosexual, less likely to smoke (6% vs 32%) and had lower median CD4 T cell counts
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than the UK participants (439 vs 640). Only 3 participants from Zambia were not on cART,
with 100% of those in the UK group having had a viral load of<40 copies/mL. There was a sig-
nificant difference between the cART regimes used, with 85% of patients in the Zambian
cohort and 47% of the UK group taking NNRTI-based cART including efavirenz and nevira-
pine (mainly in Zambia) and rilpivirine in the UK. All participants completed the study
questionnaires.
Differences in musculoskeletal symptoms between the UK and Zambian groups. Mus-
culoskeletal symptoms were common in both groups. However, no significant difference in
the presence of any joint pain was observed (UK: 69% vs Zambia: 61%, p = 0.263). Whilst sev-
eral comparisons were not statistically significant, the prevalence of symptoms was higher in
the UK population compared to Zambia for all symptoms other than burning/gritty eyes.
With regard to other symptoms, the UK group reported significantly more joint stiffness (UK:
50% vs Zambia: 40%), reduced joint movement (UK: 41% vs Zambia: 18%), muscle pain (UK:
57% vs Zambia: 38%), difficulty sleeping (UK: 52% vs Zambia: 24%) and fatigue (UK: 72% vs
Zambia: 62%) compared to the Zambian group Table 2.
Differences in physical functioning and health-related quality of life. Despite the high
frequency of musculoskeletal symptoms in both groups, all participants reported being able to
perform most activities of daily living as assessed by the HAQ, with no significant differences
in HAQ scores observed between the UK and Zambian groups (median HAQ score UK: 0 vs
Zambia: 0, p = 0.749) Table 3. Although there were no differences in the frequency of symp-
toms and the capacity to perform activities of daily living between both groups, the UK group
had significantly worse quality of life measurements compared to the Zambian group evi-
denced by lower scores on six SF-36 domains including physical functioning (UK: 90 vs Zam-
bia: 95, p = 0.024), general health (UK: 62 vs Zambia: 75, p = 0.001), vitality (UK: 50 vs
Zambia: 70, p = 0.001), social functioning (UK: 75 vs Zambia: 87.5, p = 0.018), emotional role
Table 1. Baseline characteristics.
Characteristics Brighton
(n = 108)
Zambia
(n = 106)
p-value
Age, mean (SD), years 47.6 (11.5) 44.1 (12.3) 0.034
Years since diagnosis, median (range), years 11.5 (0–35) 6 (0–40) 0.001
Gender, n (%)
Female 11 (10.2) 58 (54.7) 0.001
Male 97 (89.8) 48 (45.3)
Education, university-level education n (%) 41 (38.0) 12 (11.4) 0.001
Work status, unemployed n (%) 41 (38.3) 60 (56.4) 0.017
Smoker, n (%) 35 (32.4) 6 (6.1) 0.001
On cART, n (%) 108 (100.0) 102 (97.0) 0.222
cART Regime, n (%)
Protease inhibitor-based therapy 34 (31.5) 11 (13.9) 0.001
Integrase inhibitor-based therapy 15 (13.9) 0 (0.0)
NNRTI-based therapy 51 (47.2) 67 (84.8)
Complex regime (> 1 of above) 8 (7.4) 1 (1.3)
CD4 count, median (range), cells/mm3 640 (231–1243) 439 (41–1150) 0.001
Viral load, <40 copies/ml, n (%) 100(108) �
Comorbidities (more than 2), n (%) 71 (65.7) 27 (25.5) 0.001
� Viral load measurements not routinely available in clinical practice
https://doi.org/10.1371/journal.pone.0216787.t001
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(UK: 100 vs Zambia: 100, p = 0.003) and mental health (UK: 66 vs Zambia: 72, p = 0.001)
Table 3.
Associations between rheumatic symptoms, sociodemographic characteristics, and
quality of life measurements in the UK group. The total variance explained by the multiple
linear regression models for the UK group was 43.8%, 60.3% and 36.9% for the general health,
vitality and mental health scores respectively. Table 4. The most important predictor of poorer
general health, emotional, vitality and mental health was fatigue Table 4. Increasing joint or
muscle pain severity was also associated with poorer general health and work status (unem-
ployment) was associated with poorer mental health in the UK group.
Associations between musculoskeletal symptoms, sociodemographic characteristics,
and quality of life measurements in the Zambian group. The total variance explained by
Table 3. Stanford health assessment questionnaire (HAQ) and 36 short form survey health (SF-36) scores for the
UK and Zambia groups.
Scores; median (IQR) UK
(n = 108)
Zambia
(n = 106)
p-value
HAQ
HAQ SDI� 0 (0–0.375) 0 (0–0.375) 0.749
HAQ ADI�� 0 (0–0.375) 0 (0–0.250) 0.520
SF-36 scale scores
Physical functioning 90 (65–100) 95 (75–100) 0.024
Physical role 100 (0–100) 100 (25–100) 0.499
Bodily pain 74 (42–100) 74 (52–100) 0.493
General health 62 (42–77) 75 (55–92) 0.001
Vitality 50 (30–70) 70 (50–80) 0.001
Social functioning 75 (50–100) 87.5 (62.5–100) 0.018
Emotional role 100 (0–100) 100 (66.67–100) 0.003
Mental health 66 (48–80) 72 (56–92) 0.001
� The Standard Disability Index
��The Alternative Disability Index; HAQ = (0 = no difficulty, 1 = some difficulty, 2 = much difficulty, to 3 = unable
to do); SF-36 (0 = worst QoL; 100 = best QoL)
https://doi.org/10.1371/journal.pone.0216787.t003
Table 2. Frequency of musculoskeletal symptoms.
n (%) UK
(n = 108)
Zambia
(n = 106)
p-value
Joint pain 75 (69.4) 65 (61.2) 0.263
Muscle pain 61 (56.9) 40 (38.2) 0.012
Swollen/red joint 16 (14.7) 8 (7.8) 0.184
Reduction of joint movement 44 (40.8) 19 (18.0) 0.001
Joint stiffness 54 (50.0) 42 (39.9) 0.040
Difficulty in taking or gripping something 28 (25.5) 20 (18.6) 0.307
Burning/gritty eyes 24 (22.6) 25 (23.5) 1.000
Mouth sores 24 (22.4) 22 (20.8) 0.906
Skin rash 35 (32.4) 17 (15.8) 0.009
Nail changes 19 (17.9) 16 (14.7) 0.660
Dysuria 13 (12.3) 10 (9.9) 0.749
Difficulty sleeping 56 (52.3) 25 (23.5) 0.001
Fatigue 78 (72.0) 66 (61.8) 0.025
https://doi.org/10.1371/journal.pone.0216787.t002
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the multiple linear regression models for the Zambia group was 23.2%, 28.7.3% and 21.2% for
the general health, vitality and mental health scores respectively. Table 5. The only significant
predictor of poorer general health, vitality and mental health was fatigue Table 5.
Table 4. Summary of multiple regression analysis for variables predicting health scores for SF-36 domains in the UK group.
Variable General health Vitality Mental health
B β p value R2 B β p value R2 B β p value R2
0.438 0.603 0.369
(Constant) 73.04 <0.001 91.73 <0.001 101.27 <0.001
Demographic factors
Age (years) -0.34 -0.018 0.853 -0.029 -0.015 0.859 0.141 0.075 0.473
Gender1 11.017 0.157 0.093 -2.699 -0.036 0.639 -9.147 -0.129 0.191
Smoking2 -4.052 -0.089 0.347 -4.095 -0.085 0.284 -8.786 -0.191 0.059
Comorbidities -4.385 -0.098 0.285 2.949 0.062 0.417 -7.814 -0.173 0.077
Work status3 -2.128 -0.049 0.624 -6.720 -0.146 0.084 -12.729 -0.288 0.007
CD4 count4 0.003 0.030 0.727 -0.009 -0.090 0.222 -0.001 -0.006 0.949
Rheumatic symptoms
Reduced joint movement 1.460 0.034 0.728 -0.295 -0.006 0.937 -0.636 -0.015 0.887
Joint or muscle stiffness -5.930 -0.139 0.200 -1.267 -0.028 0.756 -1.687 -0.039 0.732
Joint or muscle pain severity5 -1.952 -0.268 0.032 -0.424 -0.055 0.594 0.226 0.031 0.814
Fatigue severity5 -2.484 -0.333 0.003 -5.229 -0.666 <0.001 -2.409 -0.320 0.006
1Reference group is male
2Reference group is non-smoker vs being a current smoker
3Reference group is current employment vs current unemployment
4Unit of CD4 count is per 1 cell higher
5Unit of severity
https://doi.org/10.1371/journal.pone.0216787.t004
Table 5. Summary of multiple regression analysis for variables predicting health scores for SF-36 domains in the Zambia group.
Variable General health Vitality Mental health
B β p value R2 B β p value R2 B β p value R2
0.232 0.287 0.212
(Constant) 69.12 <0.001 75.92 <0.001 53.245 <0.001
Demographic factors
Age (years) -0.054 -0.033 0.803 0.146 0.088 0.481 0.290 0.170 0.198
Gender1 -0.303 -0.008 -0.957 -3.227 -0.079 0.545 0.644 0.015 0.911
Smoking2 14.14 0.157 0.212 6.010 0.066 0.578 7.227 0.077 0.535
Comorbidities -7.48 -0.162 0.226 -7.379 -0.158 0.213 -7.033 -0.146 0.270
Work status3 7.49 0.185 0.149 -0.610 -0.015 0.901 4.863 0.116 0.362
CD4 count4 0.009 0.119 0.385 0.006 0.073 0.573 0.016 0.200 0.145
Rheumatic symptoms
Reduced joint movement5 8.73 0.166 0.215 -2.689 -0.050 0.688 1.559 0.028 0.829
Joint or muscle stiffness5 -2.19 -0.052 0.702 2.250 0.053 0.682 -4.800 -0.110 0.419
Joint or muscle pain severity5 -0.83 -0.130 0.356 -1.163 -0.180 0.178 -0.568 -0.085 0.540
Fatigue severity5 -2.04 -0.329 0.017 -2.608 -0.415 0.002 -1.906 -0.295 0.031
1Reference group is male
2Reference group is non-smoker vs being a current smoker
3Reference group is current employment vs current unemployment
4Unit of CD4 count is per 1 cell higher
5Unit of severity
https://doi.org/10.1371/journal.pone.0216787.t005
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Discussion
Despite effective cART, PLWH in both the UK and Zambia reported high rates of current
musculoskeletal symptoms. Pain disorders have frequently been described in PLWH with a
reported prevalence of 54% [32]. Our results are consistent with this estimate and go beyond
by reporting the rate of other musculoskeletal symptoms in two different populations of
PLWH. Musculoskeletal symptoms in PLWH can be difficult to interpret in clinical practice as
overlapping symptoms from other pain disorders such as neuropathic pain, headaches (includ-
ing a migraine), and other poorly defined pain syndromes are common [33]. Among the 214
patients included in our study, we identified fatigue, muscle and joint pain and joint stiffness
as the most common self-reported symptoms. Participants from the UK reported higher fre-
quency of almost all musculoskeletal symptoms. Possible explanations include average older
age and longer disease duration, as shown by previous larger cohorts to have a significantly
increased risk of developing rheumatic disease [34–36].
There is scanty information about the prevalence of these symptoms in the general popula-
tion of Zambia. In the UK however, musculoskeletal conditions affect 1 in 4 of the adult popu-
lation (many being young and of working age) which is around 9.6 million adults. The
prevalence of regional and widespread musculoskeletal symptoms obtained from national sur-
veys is estimated to be 28.7 per 100, rising with age to 36.6 per 100 among 70–79 years old with
rates of disabling chronic pain of 14.3% in 18–25 years old and 62% in the over 75 age group
[37, 38].
Among other musculoskeletal symptoms, fatigue was very prevalent in both groups with
rates of 72% and 62% for the UK and the Zambian groups respectively. Interestingly, fatigue
was the most common self-reported symptom and the only musculoskeletal symptom to pre-
dict poorer QoL across domains in both the UK and Zambia group. Various other studies
agree with this finding, [35, 39, 40] suggesting fatigue has one of the greatest impacts on the
QoL of PLWH [41]. Fatigue is a common symptom reported in individuals affected by other
chronic musculoskeletal and inflammatory diseases such as systemic lupus erythematosus,
seronegative and rheumatoid arthritis [42]. Whether fatigue in PLWH is influenced by the
inflammatory effects of HIV, co-existing mental health disease or medications will be impor-
tant to determine for future targeted interventions [35].
Although there were no significant differences in the impact of symptoms and the capacity
to perform activities of daily living between both groups, the UK group had significantly worse
quality of life measurements compared to the Zambian group evidenced by lower scores on six
SF-36 domains including physical functioning, general health, vitality, social functioning,
emotional role and mental health.
Perceptions on quality of life might vary by setting. A previous report looking at QoL mea-
sures across nine different resource-limited settings highlighted different cultural perceptions
or variances in baseline characteristics beyond those we have data for, such as social support
networks could account for differences in the QoL [43]. Access to specialist care, welfare, and
medications to treat pain disorders differ significantly between the UK and Zambia, as a result
individual resilience to pain and its impact on mental health and quality of life can be very dif-
ferent, which could explain some of our results.
Additionally, cultural and geographic differences in the way people respond to or under-
stand the questionnaires may account for some of these differences. The cross-cultural use and
adapated versions have however proven equally reliable and valid as their parent [23].
Although our study was not powered to validate these questionnaires, with the help of an inter-
preter items were culturally-adapted and differences in understanding was minimised.
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Many reports suggest increasing age, the presence of comorbidities and polypharmacy are
associated with a poorer QoL for PLWH [35]. We found unemployment was associated with
the worse mental health in the UK but age and presence of co-morbidities were not associated
with quality of life domains in Brighton or Zambia.
It is surprising that there is such a big difference in the proportion of participants reporting
>2 comorbidities in the two countries, particularly given the lower CD4 count among the
Zambian patients. This may reflect a difference in documentation and the feasibility to diag-
nose multiple conditions between the two populations rather than a true difference in number.
Our study has several important limitations. Firstly, the cross-sectional study design means
we are unable to conclude temporality in the associations found and should, therefore, be
interpreted with caution. Secondly, our relatively small sample size of 214 participants (108:
UK; 106: Zambia) means we may have made a type 2 error. Given the small size of the study
only some of the larger comparisons are statistically significant. Had our sample size been
larger our results may have been different. For example, although there was no significant dif-
ference in the prevalence of joint pain between the two populations, the overall prevalence dif-
ference of 8% could in fact be a true difference. It is important to highlight that our study was
not powered to detect clinically significant differences between Brighton and Lusaka and was
rather exploratory in nature. In addition, the possibility of type I errors should also be consid-
ered. Thirdly, participants were recruited by a healthcare professional through convenience
sampling. Although this is regularly used in studies related to HIV due to ongoing issues of
stigma, this may have increased the potential for selection bias. Additionally, although our
clinics are large and demographically representable of PLWH in Brighton and Lusaka, they are
only single centres and as such, limit the generalisability of our results to the local environment
rather than other institutions. Other limitations include the absence of a detailed description
of the characteristics of the pain these patients experienced, social support networks available
to them and not adjusting for other potentially important confounders, including longer dis-
ease duration, which is known to be associated with increased rates of musculoskeletal
symptoms.
On the other hand, this study is unique in its attempt to compare musculoskeletal symptom
prevalence and QoL impact in PLWH from a high and lower resource setting. Highlighting
variability in associations in different settings and areas that require attention to ensure the
best QoL for PLWH.
The mechanisms by which HIV may lead to an increased risk of pain syndromes remains
unclear, but it is likely to be multifactorial, involving biological (inflammation), psychological
and social factors [11]. Considering the high prevalence of pain syndromes in PLWH and
their impact on mental health, functional status and quality of life designing optimal and cost-
effective pathways for diagnosis and management of pain should be a priority of HIV care
regardless of the geographical setting.
The public health impact of musculoskeletal pain in PLWH cannot be underestimated.
Individuals with musculoskeletal pain are less likely to be in work than those without a health
problem and are also more likely to retire early. The direct cost to the economy on days lost of
work can be substantial as those affected by pain syndromes are more likely to utilize health-
care services and require drug prescriptions to control the symptoms [44]. Longitudinal stud-
ies in high- and low-income settings investigating the contributors of musculoskeletal pain are
needed to inform the development of effective interventions to prevent and managed those
with musculoskeletal symptoms living with HIV.
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Conclusions
In conclusion, our findings indicate that the proportion of PLWH that are affected by muscu-
loskeletal symptoms remains high, independent of the clinical setting. We have also demon-
strated a complex interplay between sociodemographic and physical symptoms on the impact
of health-related QoL.
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